These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35356661)

  • 21. Choroidal thickness after treatment for myopic 
choroidal neovascularization.
    Farinha CL; Baltar AS; Nunes SG; Franqueira NF; Figueira JP; Pires IA; Cachulo ML; Silva RM
    Eur J Ophthalmol; 2013; 23(6):887-98. PubMed ID: 23787449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. VISUAL ACUITY OUTCOMES OF RANIBIZUMAB TREATMENT IN PATHOLOGIC MYOPIC EYES WITH MACULAR RETINOSCHISIS AND CHOROIDAL NEOVASCULARIZATION.
    Ceklic L; Munk MR; Wolf-Schnurrbusch U; Gekkieva M; Wolf S
    Retina; 2017 Apr; 37(4):687-693. PubMed ID: 27533774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The other CNVM: a review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents.
    Adatia FA; Luong M; Munro M; Tufail A
    Surv Ophthalmol; 2015; 60(3):204-15. PubMed ID: 25890624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Evaluation of a Two-Year Outcome of Intravitreal Conbercept versus Ranibizumab for Pathological Myopic Choroidal Neovascularization.
    Chen C; Yan M; Huang Z; Song YP
    Curr Eye Res; 2020 Nov; 45(11):1415-1421. PubMed ID: 32191134
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation.
    Costagliola C; Semeraro F; dell'Omo R; Romano MR; Russo A; Aceto F; Mastropasqua R; Porcellini A
    Br J Ophthalmol; 2015 Jul; 99(7):1004-8. PubMed ID: 25770144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia.
    Ohno-Matsui K; Ikuno Y; Lai TYY; Gemmy Cheung CM
    Prog Retin Eye Res; 2018 Mar; 63():92-106. PubMed ID: 29111299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacotherapy of Myopic Choroidal Neovascularization.
    Isildak H; Schwartz SG; Flynn HW
    Curr Pharm Des; 2018; 24(41):4853-4859. PubMed ID: 30674251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre.
    Rishi P; Rishi E; Bhende M; Agarwal V; Vyas CH; Valiveti M; Bhende P; Rao C; Susvar P; Sen P; Raman R; Khetan V; Murali V; Ratra D; Sharma T
    Br J Ophthalmol; 2016 Oct; 100(10):1337-40. PubMed ID: 26792945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of structural and functional outcome of aflibercept versus ranibizumab in patients with myopic choroidal neovascularization.
    Howaidy A; Eldaly ZH
    Eur J Ophthalmol; 2021 Jan; 31(1):211-217. PubMed ID: 31690105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.
    Pece A; Milani P; Monteleone C; Trombetta CJ; De Crecchio G; Fasolino G; Matranga D; Cillino S; Vadalà M
    Graefes Arch Clin Exp Ophthalmol; 2015 Nov; 253(11):1867-72. PubMed ID: 25500986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Efficacy and Safety of Current Interventions for Choroidal Neovascularization Associated with Rare Diseases: A Systematic Literature Review.
    Bennett N; John L; Likhar N; Agrawal R; Amoaku WM
    Adv Ther; 2018 May; 35(5):591-603. PubMed ID: 29687336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Choroidal neovascularization secondary to pathological myopia-macular Bruch membrane defects as prognostic factor to anti-VEGF treatment.
    Coelho J; Ferreira A; Abreu AC; Monteiro S; Furtado MJ; Gomes M; Lume M
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2679-2686. PubMed ID: 33744983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H; Abrams P
    Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. APPLICATION OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY TO ASSESS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Cheng Y; Li Y; Huang X; Qu Y
    Retina; 2019 Apr; 39(4):712-718. PubMed ID: 29256987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia.
    Rishi P; Rishi E; Venkataraman A; Gopal L; Sharma T; Bhende M; Ratra D; Sen PR; Sen P
    Indian J Ophthalmol; 2011; 59(3):242-6. PubMed ID: 21586852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.
    Hayashi K; Ohno-Matsui K; Teramukai S; Shimada N; Moriyama M; Hayashi W; Yoshida T; Tokoro T; Mochizuki M
    Am J Ophthalmol; 2009 Sep; 148(3):396-408. PubMed ID: 19427991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Vascular Endothelial Growth Factor Therapy for Myopic Choroidal Neovascularization.
    Ng DSC; Lai TYY; Cheung CMG; Ohno-Matsui K
    Asia Pac J Ophthalmol (Phila); 2017; 6(6):554-560. PubMed ID: 29057641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-vascular endothelial growth factor for myopic choroidal neovascularization.
    Ng DS; Kwok AK; Chan CW
    Clin Exp Ophthalmol; 2012; 40(1):e98-e110. PubMed ID: 21902785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment Patterns for Myopic Choroidal Neovascularization in the United States: Analysis of the IRIS Registry.
    Willis J; Morse L; Vitale S; Parke DW; Rich WL; Lum F; Cantrell RA
    Ophthalmology; 2017 Jul; 124(7):935-943. PubMed ID: 28372860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.